Related references
Note: Only part of the references are listed.Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice
Eu Jeong Ku et al.
DIABETES OBESITY & METABOLISM (2019)
Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial
Michael E. J. Lean et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study
Eu Jeong Ku et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis
Yechen Han et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial
David R. Matthews et al.
LANCET (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Brendan L. Neuen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin
Stefano Del Prato et al.
DIABETES OBESITY & METABOLISM (2018)
A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study
Russell Scott et al.
DIABETES OBESITY & METABOLISM (2018)
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis
Sean L. Zheng et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Katherine R. Tuttle et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Bernhard Ludvik et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
Hertzel C. Gerstein et al.
CIRCULATION (2018)
Efficacy and Safety of Initial Combination Therapy in Treatment-Na⟨ve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis
Xiaoling Cai et al.
DIABETES THERAPY (2018)
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke Post Hoc Analysis From the LEADER Trial
Subodh Verma et al.
CIRCULATION (2018)
Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
Bancha Satirapoj et al.
PLOS ONE (2018)
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
Ofri Mosenzon et al.
DIABETES CARE (2017)
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
Sultan Linjawi et al.
DIABETES THERAPY (2017)
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
Sultan Linjawi et al.
DIABETES THERAPY (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM)
Marcello Casaccia Bertoluci et al.
DIABETOLOGY & METABOLIC SYNDROME (2017)
Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis
Wen Wang et al.
SCIENTIFIC REPORTS (2017)
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial
Olga Vaccaro et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE)
Zubin Punthakee et al.
DIABETES CARE (2016)
Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials
U. Anyanwagu et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
Dimitris Varvaki Rados et al.
PLOS MEDICINE (2016)
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
Juan P. Frias et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
Ralph A. DeFronzo et al.
DIABETES CARE (2015)
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial
M. A. Abdul-Ghani et al.
DIABETES OBESITY & METABOLISM (2015)
Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients
G. McInnes et al.
DIABETES OBESITY & METABOLISM (2015)
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Faiez Zannad et al.
LANCET (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis
Jun-Ichiro Mera et al.
JOURNAL OF DIABETES AND METABOLIC DISORDERS (2015)
Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes
Yuya Nakamura et al.
HEMODIALYSIS INTERNATIONAL (2014)
The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18 980 patients with type-2 diabetes mellitus-a meta-analysis
Xia Liu et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2014)
Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial
Juan C. Arjona Ferreira et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2013)
Long-Term Effects of Alogliptin Benzoate in Hemodialysis Patients with Diabetes: A 2-year Study
Yuya Nakamura et al.
NEPHRON CLINICAL PRACTICE (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis
Caroline Kaercher Kramer et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register
Nils Ekstrom et al.
BMJ OPEN (2012)
Efficacy and Safety of Insulin Glargine in Type 2 Diabetic Patients with Renal Failure
Mitra Niafar et al.
JOURNAL OF DIABETES & METABOLISM (2012)
Effect of Antihyperglycemic Agents Added to Metformin and a Sulfonylurea on Glycemic Control and Weight Gain in Type 2 Diabetes: A Network Meta-analysis
Jorge L. Gross et al.
ANNALS OF INTERNAL MEDICINE (2011)
Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure
Charlotte Andersson et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Physical Activity Advice Only or Structured Exercise Training and Association With HbA1c Levels in Type 2 Diabetes A Systematic Review and Meta-analysis
Daniel Umpierre et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis
Pantelis A. Sarafidis et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2010)
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
J. C. N. Chan et al.
DIABETES OBESITY & METABOLISM (2008)
Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes:: a multicentre randomised parallel-group trial
Jianping Weng et al.
LANCET (2008)
Paget's disease of the mandible
Mayank B. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials
Rodrigo M. Lago et al.
LANCET (2007)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
DM Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients
G Schernthaner et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Share Paper
